Cyclacel Pharmaceuticals, Inc. Form 5 Febru FC

February 17,	2015										
FORM									OMB AF	PROVAL	
Check this no longer	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number: Expires:	3235-0362 January 31, 2005				
to Section Form 4 or 5 obligatio may contin <i>See</i> Instruc	Form ANN ons nue.		TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					FICIAL	Estimated average burden hours per response 1.0		
1(b).	Filed purs ^{oldings} Section 17(a	a) of the F	Public Ut		g Compa	ny A	ct of 1		n		
1. Name and Address of Reporting Person <u>*</u> Rombotis Spiro George			-					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (N	fiddle)						rector 10% Owner ficer (give title Other (specify below)			
200 CONNI 1500	ELL DRIVE, SUI	TE	12/31/20	014				Pres	sident & CEO		
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				Original		6. Individual or Joint/Group Reporting (check applicable line)				
BERKELEY HEIGHTS,Â	Y À NJÂ 07922						-	_X_ Form Filed by 0 Form Filed by N Person			
(City)	(State)	(Zip)	Tabl	e I - Non-Deri	ivative Sec	urities	s Acqui	ired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	y (Month/Day/Year) Execution 3) any		med 3. on Date, if Transaction Code Day/Year) (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock,		Ŷ		7	2 001		\$		D	â	

value per share

\$0.001 par

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

12/06/2014

Â

F

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

237,525 <u>(2)</u> D

D

(1)

3,891

\$

2.99

SEC 2270 (9-02)

Â

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 5

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
1. 9	Director	10% Owner	Officer	Other			
Rombotis Spiro George 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS, NJ 07922		Â	President & CEO	Â			

Signatures

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reduction adjustment to previously reported Restricted Stock Unit award with regard to Federal and state withholding taxes paid by the Company on behalf of the employee.
- (2) Of the shares of common stock reported, 142 shares are held indirectly by Mr. Rombotis through his IRA account.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.